AR106040A1 - Moduladores de la proteína core de la hepatitis b - Google Patents

Moduladores de la proteína core de la hepatitis b

Info

Publication number
AR106040A1
AR106040A1 ARP160102819A ARP160102819A AR106040A1 AR 106040 A1 AR106040 A1 AR 106040A1 AR P160102819 A ARP160102819 A AR P160102819A AR P160102819 A ARP160102819 A AR P160102819A AR 106040 A1 AR106040 A1 AR 106040A1
Authority
AR
Argentina
Prior art keywords
6alkyl
group
optionally substituted
halogen
hydroxyl
Prior art date
Application number
ARP160102819A
Other languages
English (en)
Inventor
Francis Samson
Haydar Simon
Bures Mark
Li Leping
Maag Hans
Arnold Lee
Turner William
Original Assignee
Assembly Biosciences Inc
Univ Indiana Res & Tech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Assembly Biosciences Inc, Univ Indiana Res & Tech Corp filed Critical Assembly Biosciences Inc
Publication of AR106040A1 publication Critical patent/AR106040A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/38—[b, e]- or [b, f]-condensed with six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/16—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D267/20—[b, f]-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D281/16—[b, f]-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

Reivindicación 1: Un compuesto caracterizado porque representado mediante la fórmula (1), donde Y se selecciona del grupo que consiste en S(O)ʸ, C=O, C(R¹¹)₂, NRY y O donde y es 0, 1 ó 2; R¹¹, en cada caso, se selecciona del grupo que consiste en H, halógeno, y C₁₋₆alquilo (opcionalmente sustituido con uno, dos o tres halógenos); RY se selecciona del grupo que consiste en H, metilo, etilo, propilo, propenilo, butilo, fenilo y bencilo, donde RY, cuando no es H, puede estar opcionalmente sustituido con hidroxilo; RZ se selecciona del grupo que consiste en H, metilo, etilo, propilo, fenilo y bencilo; Rᵐ’ y Rᵐ se seleccionan en forma independiente entre sí del grupo que consiste en H, C₁₋₆alquilo (opcionalmente sustituido con uno, dos o tres sustituyentes seleccionados cada uno de forma independiente entre halógeno e hidroxilo), y C₂₋₆alquenilo (opcionalmente sustituido con uno, dos o tres sustituyentes seleccionados cada uno de forma independiente entre halógeno e hidroxilo); Rᶜ se selecciona del grupo que consiste en H, C₁₋₆alquilo y C₂₋₆alquenilo; R⁷⁷ se selecciona del grupo que consiste en H, halógeno, ciano, y C₁₋₆alquilo; R⁷⁸ se selecciona del grupo que consiste en H, halógeno, ciano, C₁₋₆alquilo, carboxi, -C(O)-O-C₁₋₆alquilo; C₃₋₆cicloalquilo, -NR’R’’; fenilo (opcionalmente sustituido con uno, dos, tres o cuatro sustituyentes seleccionados cada uno de forma independiente del grupo que consiste en R⁷³); bencilo (opcionalmente sustituido con uno o más sustituyentes seleccionados cada uno de forma independiente del grupo que consiste en R⁷³), heterociclo de 4 - 7 miembros (opcionalmente sustituido con uno o más sustituyentes seleccionados cada uno de forma independiente del grupo que consiste en R⁷³); heteroarilo monocíclico de 4 - 7 miembros (opcionalmente sustituido con uno o más sustituyentes seleccionados cada uno de forma independiente del grupo que consiste en R⁷³); heteroarilo bicíclico de 9 - 10 miembros (opcionalmente sustituido con uno o más sustituyentes seleccionados cada uno de forma independiente del grupo que consiste en R⁷³), X²-R⁷⁹, y X²-C₁₋₆alquilen-R⁷⁹; X² se selecciona del grupo que consiste en S(O)ʷ (donde w es 0, 1, ó 2), O, -C(O)- y NR’; R⁷⁹ se selecciona del grupo que consiste en H, hidroxilo, halógeno, C₁₋₆alquilo, -C(O)-O-C₁₋₆alquilo, heterociclo (opcionalmente sustituido con uno o más sustituyentes seleccionados del grupo que consiste en halógeno, NR’R’’, -C(O)-O-C₁₋₆alquilo, carboxi y C₁₋₆alquilo), -C(O)-NR’R’’, -C(=NH)-NR’R’’, heteroarilo, fenilo (opcionalmente sustituido con uno o más sustituyentes seleccionados del grupo que consiste en halógeno, NR’R’’, -C(O)-O-C₁₋₆alquilo, carboxi, C₁₋₆alcoxi, y C₁₋₆alquilo), C₂₋₆alquenilo, C₂₋₆alquinilo, C₁₋₆alcoxi, carboxi, NR’R’’, -C(O)-C₁₋₆alquilo, C₃₋₆cicloalquilo, -NR’-C(O)-C₁₋₆alquilo, NR’-C(O)-O-C₁₋₆alquilo, -S(O)ʷ-C₁₋₆alquilo (donde w es 0, 1 ó 2), -S(O)ʷ-NR’R’’ (donde w es 0, 1 ó 2), y -NR’-S(O)ʷ-C₁₋₆alquilo (donde w es 0, 1 ó 2)); R⁷³ se selecciona del grupo que consiste en H, halógeno, hidroxilo, nitro, ciano, carboxi, oxo, C₁₋₆alquilo, -C(O)-O-C₁₋₆alquilo, heterociclo (opcionalmente sustituido con uno o más sustituyentes seleccionados del grupo que consiste en halógeno, hidroxilo, oxo, NR’R’’, -C(O)-O-C₁₋₆alquilo, carboxi y C₁₋₆alquilo), -C(O)-NR’-C₁₋₆alquilo, -C(=NH)-NR’R’’, heteroarilo, fenilo, C₂₋₆alquenilo, C₂₋₆alquinilo, C₁₋₆alcoxi, carboxi, oxo, NR’R’’, -C(O)-C₁₋₆alquilo, -C₃₋₆cicloalquilo, NR’-C(O)-C₁₋₆alquilo, NR’-C(O)-O-C₁₋₆alquilo, -S(O)ʷ-C₁₋₆alquilo (donde w es 0, 1 ó 2), -S(O)ʷ-NR’R’’ (donde w es 1, 2 ó 3), -NR’-S(O)ʷ-C₁₋₆alquilo (donde w es 0, 1 ó 2), C(O)-NR’-C₁₋₆alquilo, C(O)-C₁₋₃alquilen-NR’-C(O)-O-C₁₋₆alquilo, X²-R⁷⁹; y X²-C₁₋₆alquilen-R⁷⁹; R’ se selecciona, en forma independiente en cada caso, entre H, metilo, etilo, ciclopropilo, ciclobutilo, y propilo; R’’ se selecciona, en forma independiente en cada caso, entre H, metilo, etilo, propilo (opcionalmente sustituido con hidroxilo), butilo (opcionalmente sustituido con hidroxilo), -C(O)-metilo y -C(O)-etilo, o R’ y R’’ tomados junto con el nitrógeno al cual están unidos pueden formar un heterociclo de 4 - 7 miembros opcionalmente sustituido con uno, dos o más sustituyentes seleccionados del grupo que consiste en halógeno, hidroxilo, NH₂, -C(O)-O-C₁₋₃alquilo, -C(O)-C₁₋₃alquilo, carboxi, oxo, y C₁₋₃alquilo; cada una de las porciones R⁴, R⁵, R⁶, R⁷, R⁸, R⁹, y R¹⁰ se selecciona en forma independiente en cada caso entre el grupo que consiste en hidrógeno, C₁₋₆alquilo, C₁₋₆alcoxi, C₂₋₆alquinilo, C₂₋₆alquenilo, halógeno, hidroxilo, nitro, ciano, y NR’R’’; donde en cada caso, C₁₋₆alquilo, C₂₋₆alquenilo o C₂₋₆alquinilo puede estar opcionalmente sustituido con uno, dos, tres o más sustituyentes seleccionados del grupo que consiste en halógeno, hidroxilo, nitro, ciano, carboxi, C₃₋₆cicloalquilo, C₂₋₄alquenilo, C₂₋₄alquinilo, C₁₋₃alcoxi, NR’R’’, -NR’-S(O)ʷ-C₁₋₂alquilo (donde w es 0, 1 ó 2), NR’-C(O)-C₁₋₃alquilo, NR’-C(O)-O-C₁₋₃alquilo, y S(O)ʷ-NR’R’’ (donde w es 0, 1 ó 2); C₁₋₆alcoxi puede estar opcionalmente sustituido con uno, dos, tres o más sustituyentes seleccionados del grupo que consiste en halógeno, hidroxilo, nitro, ciano, carboxi, C₁₋₃alquilo, NR’R’’, -NR’-S(O)ʷ-C₁₋₂alquilo (donde w es 0, 1 ó 2), y S(O)ʷ-NR’R’’ (donde w es 0, 1 ó 2); C₁₋₆alquileno puede estar opcionalmente sustituido con un sustituyente seleccionado entre el grupo que consiste en C₃₋₆ cicloalquilo, hidroxilo, ciano, y halógeno; y sales aceptables farmacéuticamente y N-óxidos del mismo.
ARP160102819A 2015-09-15 2016-09-15 Moduladores de la proteína core de la hepatitis b AR106040A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562218815P 2015-09-15 2015-09-15

Publications (1)

Publication Number Publication Date
AR106040A1 true AR106040A1 (es) 2017-12-06

Family

ID=58289869

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP160102819A AR106040A1 (es) 2015-09-15 2016-09-15 Moduladores de la proteína core de la hepatitis b
ARP160102816A AR106037A1 (es) 2015-09-15 2016-09-15 Moduladores de la proteína core de la hepatitis b
ARP160102820A AR106041A1 (es) 2015-09-15 2016-09-15 Moduladores de la proteína core de la hepatitis b

Family Applications After (2)

Application Number Title Priority Date Filing Date
ARP160102816A AR106037A1 (es) 2015-09-15 2016-09-15 Moduladores de la proteína core de la hepatitis b
ARP160102820A AR106041A1 (es) 2015-09-15 2016-09-15 Moduladores de la proteína core de la hepatitis b

Country Status (28)

Country Link
US (6) US10377748B2 (es)
EP (4) EP3349580B1 (es)
JP (4) JP2018531919A (es)
KR (3) KR20180053363A (es)
CN (4) CN108347942B (es)
AR (3) AR106040A1 (es)
AU (4) AU2016323297A1 (es)
CA (3) CA2998803A1 (es)
CL (2) CL2018000684A1 (es)
CY (1) CY1123570T1 (es)
DK (1) DK3349580T3 (es)
DO (1) DOP2018000074A (es)
EA (3) EA201890736A1 (es)
ES (2) ES2831333T3 (es)
HK (3) HK1258761A1 (es)
HR (1) HRP20201812T1 (es)
HU (1) HUE051872T2 (es)
IL (3) IL258099A (es)
LT (1) LT3349580T (es)
MX (4) MX2018003207A (es)
PH (3) PH12018500572A1 (es)
PT (1) PT3349580T (es)
RS (1) RS61064B1 (es)
SG (1) SG10202011103UA (es)
SI (1) SI3349580T1 (es)
TW (4) TW201720802A (es)
WO (3) WO2017048950A1 (es)
ZA (1) ZA201802456B (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015138895A1 (en) 2014-03-13 2015-09-17 Indiana University Research And Technology Corporation Hepatitis b core protein allosteric modulators
TW201720802A (zh) * 2015-09-15 2017-06-16 艾森伯利生物科學公司 B型肝炎核心蛋白質調節劑
US10987360B2 (en) 2016-09-15 2021-04-27 Assembly Biosciences, Inc. Hepatitis B core protein modulators
AU2017342536A1 (en) 2016-10-14 2019-05-02 Precision Biosciences, Inc. Engineered meganucleases specific for recognition sequences in the Hepatitis B virus genome
CA3040919A1 (en) 2016-11-07 2018-05-11 Arbutus Biopharma Corporation Substituted pyridinone-containing tricyclic compounds, and methods using same
BR112019017603A2 (pt) * 2017-02-23 2020-03-24 Fujian Cosunter Pharmaceutical Co., Ltd. Composto de tri-ciclo e aplicações do mesmo
SG11201908012SA (en) 2017-03-02 2019-09-27 Assembly Biosciences Inc Cyclic sulfamide compounds and methods of using same
CN110612300B (zh) 2017-03-13 2023-10-20 组装生物科学股份有限公司 制备乙型肝炎核心蛋白调节剂的方法
AU2018238138A1 (en) 2017-03-21 2019-10-17 Arbutus Biopharma Corporation Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same
KR20200083551A (ko) 2017-11-02 2020-07-08 아이쿠리스 게엠베하 운트 코. 카게 B형 간염 바이러스 (hbv)에 활성인 신규 고활성 아미노-티아졸 치환된 인돌-2-카르복스아미드
EP3704119A1 (en) 2017-11-02 2020-09-09 AiCuris GmbH & Co. KG Novel, highly active pyrazolo-piperidine substituted indole-2-carboxamides active against the hepatitis b virus (hbv)
AU2018392212B9 (en) 2017-12-20 2021-03-18 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein
KR102492187B1 (ko) 2017-12-20 2023-01-27 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. Sting 어댑터 단백질을 활성화하는 포스포네이트 결합을 가진 3'3' 사이클릭 다이뉴클레오티드
CN111788204B (zh) 2018-02-26 2023-05-05 吉利德科学公司 作为hbv复制抑制剂的取代吡咯嗪化合物
WO2019195181A1 (en) 2018-04-05 2019-10-10 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis b virus protein x
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 ２，２，─環二核苷酸
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
KR20200140867A (ko) 2018-04-06 2020-12-16 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. 3'3'-사이클릭 다이뉴클레오티드
TW201945388A (zh) 2018-04-12 2019-12-01 美商精密生物科學公司 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶
CA3099138A1 (en) * 2018-05-03 2019-11-07 Emory University Modulators of orphan nuclear receptors for nash and other metabolic disorders
US20190359645A1 (en) 2018-05-03 2019-11-28 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide
TWI815887B (zh) * 2018-05-15 2023-09-21 美商愛彼特生物製藥股份有限公司 經取代的2,2'-雙嘧啶基化合物、其類似物及其使用方法
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
WO2020092528A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
MX2021005047A (es) 2018-10-31 2021-09-08 Gilead Sciences Inc Compuestos de 6-azabenzimidazol sustituidos como inhibidores de hpk1.
TW202031666A (zh) 2018-11-02 2020-09-01 德商艾庫瑞斯公司 對抗b型肝炎病毒(hbv)之新穎6,7-二氫-4h-噻唑并[5,4-c]吡啶脲活性劑
UY38435A (es) 2018-11-02 2020-05-29 Aicuris Gmbh & Co Kg Nuevas urea 6,7-dihidro-4h-pirazol[1,5-a] pirazinas activas contra el virus de la hepatitis b (vhb)
AR116947A1 (es) 2018-11-02 2021-06-30 Aicuris Gmbh & Co Kg Derivados de urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas-indol-2-carboxamidas activas contra el virus de la hepatitis b (vhb)
UY38437A (es) 2018-11-02 2020-05-29 Aicuris Gmbh & Co Kg Nuevas urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas activas contra el virus de la hepatitis b (hbv)
AR116946A1 (es) 2018-11-02 2021-06-30 Aicuris Gmbh & Co Kg Derivados de urea 6,7-dihidro-4h-pirazolo[4,3-c]piridinas activas contra el virus de la hepatitis b (vhb)
UY38434A (es) 2018-11-02 2020-05-29 Aicuris Gmbh & Co Kg Nuevas 6,7-dihidro-4h-pirazolo[1,5-a]pirazin indol-2-carboxamidas activas contra el virus de la hepatitis b (hbv)
TWI827760B (zh) 2018-12-12 2024-01-01 加拿大商愛彼特生物製藥公司 經取代之芳基甲基脲類及雜芳基甲基脲類、其類似物及其使用方法
CN113543851A (zh) 2019-03-07 2021-10-22 捷克共和国有机化学与生物化学研究所 2’3’-环二核苷酸及其前药
EP3935066A1 (en) 2019-03-07 2022-01-12 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
US11766447B2 (en) 2019-03-07 2023-09-26 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
KR20220002499A (ko) 2019-04-30 2022-01-06 아이쿠리스 게엠베하 운트 코. 카게 B형 간염 바이러스 (hbv)에 대해 활성인 신규 페닐 및 피리딜 우레아
CA3138643A1 (en) 2019-04-30 2020-11-05 Aicuris Gmbh & Co. Kg Novel indole-2-carboxamides active against the hepatitis b virus (hbv)
US20220227737A1 (en) 2019-04-30 2022-07-21 Aicuris Gmbh & Co. Kg Novel oxalyl piperazines active against the hepatitis b virus (hbv)
WO2020221824A1 (en) 2019-04-30 2020-11-05 Aicuris Gmbh & Co. Kg Novel indolizine-2-carboxamides active against the hepatitis b virus (hbv)
EP3972695A1 (en) 2019-05-23 2022-03-30 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
JP2022532935A (ja) * 2019-05-24 2022-07-20 アッセンブリー バイオサイエンシズ，インコーポレイテッド Ｈｂｖの処置のための医薬組成物
CN114245807A (zh) 2019-06-25 2022-03-25 吉利德科学公司 Flt3l-fc融合蛋白和使用方法
EP4017476A1 (en) 2019-08-19 2022-06-29 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
WO2021067181A1 (en) 2019-09-30 2021-04-08 Gilead Sciences, Inc. Hbv vaccines and methods treating hbv
EP4063366A4 (en) * 2019-11-22 2023-12-20 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. CRYSTAL FORM OF NUCLEOPROTEIN INHIBITOR AND USE THEREOF
US20230031465A1 (en) 2019-12-06 2023-02-02 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
EP4118070A4 (en) * 2020-03-11 2024-04-10 Nocion Therapeutics Inc CHARGED ION CHANNEL BLOCKERS AND METHODS OF USE
JP2023518433A (ja) 2020-03-20 2023-05-01 ギリアード サイエンシーズ， インコーポレイテッド ４’－ｃ－置換－２－ハロ－２’－デオキシアデノシンヌクレオシドのプロドラッグ並びにその製造法及び使用法
BR112022021419A2 (pt) * 2020-04-22 2023-03-07 Assembly Biosciences Inc Compostos de heteroaril carboxamida de 5 membros para o tratamento de hbv
CN113929648A (zh) * 2020-07-14 2022-01-14 浙江晖石药业有限公司 一种环丁烷-1,2-二甲酸酐及其中间体的制备方法
CR20230071A (es) 2020-08-07 2023-04-11 Gilead Sciences Inc Profármacos de análogos de nucleótidos de fosfonamida y su uso farmacéutico
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
WO2022241134A1 (en) 2021-05-13 2022-11-17 Gilead Sciences, Inc. COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS
IL309378A (en) 2021-06-23 2024-02-01 Gilead Sciences Inc DIACYLGLYERCOL KINASE MODULATING COMPOUNDS
CN117396478A (zh) 2021-06-23 2024-01-12 吉利德科学公司 二酰基甘油激酶调节化合物
EP4359411A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271684A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CN115521238A (zh) * 2022-07-02 2022-12-27 甘肃瀚聚药业有限公司 一种n-甲基-2-(2-氯乙基)吡咯烷的制备方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US688762A (en) * 1901-06-19 1901-12-10 Charles Weber Toy.
GB1480553A (en) 1976-06-03 1977-07-20 Pfizer Ltd Tricyclic sulphonamides
JPS58225074A (ja) 1982-06-25 1983-12-27 Chugai Pharmaceut Co Ltd ジベンゾオキサゼピン誘導体
GB9109557D0 (en) 1991-05-02 1991-06-26 Wellcome Found Chemical compounds
US5512563A (en) 1993-07-29 1996-04-30 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
DE19624659A1 (de) * 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalken- und Pyridylalkinsäureamide
DE102004004928A1 (de) 2004-01-31 2005-08-18 Bayer Healthcare Ag Dibenzoxazepine II
US20070105819A1 (en) * 2005-10-17 2007-05-10 Roger Olsson CB-1 modulating compounds and their use
US20070105835A1 (en) * 2005-11-07 2007-05-10 Kazantsev Aleksey G Compositions and methods for modulating poly(ADP-ribose) polymerase activity
JP4042065B1 (ja) 2006-03-10 2008-02-06 健治 吉田 情報処理装置への入力処理システム
US20100022509A1 (en) * 2006-06-07 2010-01-28 Fahey Robert C Inhibitors of MshC and Homologs Thereof, and Methods of Identifying Same
WO2008118141A2 (en) 2006-10-17 2008-10-02 Acadia Pharmaceuticals Inc. Use of cannabinoid modulating compounds in combination with other therapeutic compounds for adjunctive therapy
AU2009274255A1 (en) 2008-07-23 2010-01-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibitors of the plasmodial surface anion channel as antimalarials
US9040508B2 (en) * 2008-12-08 2015-05-26 Vm Pharma Llc Compositions of protein receptor tyrosine kinase inhibitors
CN104341401B (zh) * 2009-12-18 2017-02-15 北京凯因科技股份有限公司 C型肝炎病毒复制的新型抑制剂
WO2012045194A1 (en) 2010-10-09 2012-04-12 Abbott Laboratories Benzodiazepinones as fak inhibitors for treatment of cancer
EP2726459B1 (en) 2011-07-01 2019-09-11 Baruch S. Blumberg Institute Sulfamoylbenzamide derivatives as antiviral agents against hbv infection
US9968650B2 (en) 2011-07-13 2018-05-15 Indiana University Research And Technology Corporation Modified viral structural protein with antiviral activity
JP6162144B2 (ja) 2012-01-06 2017-07-19 ヤンセン・サイエンシズ・アイルランド・ユーシー ４，４−二置換−１，４−ジヒドロピリミジン、及びｂ型肝炎の処置のための医薬としてのその使用
SG10201605291WA (en) 2012-08-28 2016-08-30 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
AU2013307328B2 (en) 2012-08-28 2017-10-19 Janssen Sciences Ireland Uc Fused bicyclic sulfamoyl derivatives and the use thereof as medicaments for the treatment of hepatitis B
PE20150776A1 (es) 2012-09-10 2015-05-21 Hoffmann La Roche 6-aminoacido-heteroarildihidropirimidinas para el tratamiento y profilaxis de la infeccion del virus de la hepatitis b
EP2917184A4 (en) 2012-11-09 2016-06-29 Univ Indiana Res & Tech Corp ALTERNATIVE USES FOR HBV ARRANGEMENT EFFECTORS
NZ748966A (en) 2012-12-06 2020-05-29 Baruch S Blumberg Inst Functionalized benzamide derivatives as antiviral agents against hbv infection
KR101942151B1 (ko) 2012-12-27 2019-01-24 드렉셀유니버시티 Hbv 감염에 대한 항바이러스 물질
RU2519546C1 (ru) 2013-01-16 2014-06-10 Общество С Ограниченной Ответственностью "Биоинтегратор" (Ооо "Биоинтегратор") КОНЪЮГАТЫ И МАЛЫЕ МОЛЕКУЛЫ, ВЗАИМОДЕЙСТВУЮЩИЕ С РЕЦЕПТОРОМ CD16а
HUE034820T2 (en) 2013-02-28 2018-02-28 Janssen Sciences Ireland Uc Sulphamoyl arylamides and their use as medicaments for the treatment of hepatitis B
AR095426A1 (es) 2013-03-14 2015-10-14 Onyx Therapeutics Inc Inhibidores tripeptídicos de la epoxicetona proteasa
ES2892423T3 (es) 2013-03-15 2022-02-04 Celgene Car Llc Compuestos de heteroarilo y usos de los mismos
BR112015025052A2 (pt) 2013-04-03 2021-07-06 Janssen Sciences Ireland Uc derivados de n-fenil-carboxamida e o seu uso como medicamentos para o tratamento da hepatite b
PL2997019T3 (pl) 2013-05-17 2019-03-29 Janssen Sciences Ireland Uc Pochodne sulfamoilotiofenamidu i ich zastosowanie jako leków do leczenia wirusowego zapalenia wątroby typu B
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
BR112015028873A2 (pt) 2013-05-17 2017-07-25 Hoffmann La Roche heteroaril-diidro-pirimidinas interligados na posição 6, para o tratamento e profilaxia de infecção pelo vírus da hepatite b
WO2014205138A1 (en) 2013-06-19 2014-12-24 Seragon Pharmaceuticals, Inc. Estrogen receptor modulator and uses thereof
WO2015017412A1 (en) * 2013-07-29 2015-02-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 11-oxo-10,11-dihydrodibenzo[b,f][1,4]thiazepine s-oxide derivatives and their use as dopamine d2 receptor antagonists
WO2015138895A1 (en) 2014-03-13 2015-09-17 Indiana University Research And Technology Corporation Hepatitis b core protein allosteric modulators
MX2016016405A (es) 2014-06-10 2017-04-06 Basf Se Compuestos de [1,2,4]triazol e imidazol sustituidos como fungicidas.
TW201720802A (zh) * 2015-09-15 2017-06-16 艾森伯利生物科學公司 B型肝炎核心蛋白質調節劑

Also Published As

Publication number Publication date
JP7023838B2 (ja) 2022-03-31
TW202208353A (zh) 2022-03-01
PH12018500572A1 (en) 2018-09-17
AU2021202065B2 (en) 2022-07-28
CN108347942A (zh) 2018-07-31
JP2018531918A (ja) 2018-11-01
JP2018531921A (ja) 2018-11-01
IL258097A (en) 2018-05-31
EP3349761A4 (en) 2019-03-06
EA201890735A1 (ru) 2018-10-31
US10377748B2 (en) 2019-08-13
AR106037A1 (es) 2017-12-06
KR20180050406A (ko) 2018-05-14
EP3349580A1 (en) 2018-07-25
AR106041A1 (es) 2017-12-06
AU2016323305A1 (en) 2018-04-12
US20240025890A1 (en) 2024-01-25
LT3349580T (lt) 2020-12-28
US10392379B2 (en) 2019-08-27
US20200131168A1 (en) 2020-04-30
JP2018531919A (ja) 2018-11-01
WO2017048962A1 (en) 2017-03-23
CN108348529A (zh) 2018-07-31
ES2905950T3 (es) 2022-04-12
US11814376B2 (en) 2023-11-14
SI3349580T1 (sl) 2021-01-29
EP3349581B8 (en) 2022-01-05
CN108347943B (zh) 2020-07-10
WO2017048950A1 (en) 2017-03-23
HK1258697A1 (zh) 2019-11-15
US10968211B2 (en) 2021-04-06
KR20180053363A (ko) 2018-05-21
EP3349581A4 (en) 2019-04-24
US20180265484A1 (en) 2018-09-20
CA2998793A1 (en) 2017-03-23
AU2016323293B2 (en) 2021-04-29
DK3349580T3 (da) 2020-11-16
AU2021202065A1 (en) 2021-04-29
JP2021054872A (ja) 2021-04-08
CA2998803A1 (en) 2017-03-23
AU2016323293A1 (en) 2018-04-05
IL258124B (en) 2021-02-28
US20180273520A1 (en) 2018-09-27
CN108347943A (zh) 2018-07-31
US20180258084A1 (en) 2018-09-13
MX2018003206A (es) 2018-09-06
IL258124A (en) 2018-05-31
RS61064B1 (sr) 2020-12-31
TW201718570A (zh) 2017-06-01
HK1259141A1 (zh) 2019-11-29
MX2018003207A (es) 2018-08-21
PH12018500573A1 (en) 2018-09-17
KR20180050405A (ko) 2018-05-14
CY1123570T1 (el) 2021-10-29
EP3349581B1 (en) 2021-12-01
PT3349580T (pt) 2020-11-24
CA2998741A1 (en) 2017-03-23
EA201890736A1 (ru) 2018-10-31
MX2022005899A (es) 2022-06-27
JP7150903B2 (ja) 2022-10-11
EP3349581A1 (en) 2018-07-25
CN112094264A (zh) 2020-12-18
TW201720802A (zh) 2017-06-16
ES2831333T3 (es) 2021-06-08
US10766890B2 (en) 2020-09-08
WO2017048954A1 (en) 2017-03-23
IL258099A (en) 2018-05-31
TWI721016B (zh) 2021-03-11
ZA201802456B (en) 2022-12-21
EA201890731A1 (ru) 2018-10-31
CL2018000684A1 (es) 2018-12-28
CL2019001433A1 (es) 2019-09-27
TWI786639B (zh) 2022-12-11
EP3349580B1 (en) 2020-08-19
HRP20201812T1 (hr) 2021-03-19
PH12018500571A1 (en) 2018-10-01
US20230044112A1 (en) 2023-02-09
EP3349761B1 (en) 2022-01-26
TW201720820A (zh) 2017-06-16
HUE051872T2 (hu) 2021-03-29
CA2998741C (en) 2024-01-16
HK1258761A1 (zh) 2019-11-22
CN108347942B (zh) 2021-09-03
EP3349580A4 (en) 2019-05-15
EP3349761A1 (en) 2018-07-25
TWI730985B (zh) 2021-06-21
EP3782626A1 (en) 2021-02-24
DOP2018000074A (es) 2018-06-30
AU2016323297A1 (en) 2018-04-12
SG10202011103UA (en) 2020-12-30
MX2018003198A (es) 2018-08-23

Similar Documents

Publication Publication Date Title
AR106040A1 (es) Moduladores de la proteína core de la hepatitis b
ES2620668T3 (es) Derivados de amidas y sulfonamidas amido espirocíclicas
CL2017002908A1 (es) Amidas heterocíclicas como inhibidores de quinasa.
AR108130A1 (es) Derivados de pirazolopirimidina
DK3359542T3 (da) Spiro[3h-indol-3,2'-pyrrolidin]-2(1h)-on-forbindelser og derivater som mdm2-p53-inhibitorer
CL2013003344A1 (es) Compuestos derivados de piridin-2(1h)-ona sustituidos, inhibidores de quinasas jak; composicion farmaceutica que los comprende; combinacion farmaceutica; utiles en el tratamiento de enfermedades mieloproliferatavas, leucemia, rechazo de trasplantes, enfermedades mediadas por el sistema inmune, entre otras.
ES2684517T3 (es) Compuestos de heterociclilo como inhibidores de MEK
AR110405A1 (es) Compuestos
AR092349A1 (es) Imidazotriazincarbonitrilos utiles como inhibidores de quinasa
NI201500119A (es) Compuestos de heteroarilo y sus usos
AR099913A1 (es) Derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
AR118123A2 (es) Derivados de isoxazolidina, proceso para preparar dichos compuestos, composición farmacéutica y combinación
PE20130306A1 (es) Morfolinopirimidinas y su uso en terapia
AR106211A1 (es) Derivados de pirazol activos como pesticida
AR084553A1 (es) DERIVADOS IMIDAZOLICOS HETEROCICLICOS INHIBIDORES DE b-SECRETASA, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y USO DE LOS MISMOS PARA TRATAR ENFERMEDADES NEURODEGENERATIVAS, EN PARTICULAR ALZHEIMER
UY31711A (es) Nuevos derivados de carbazol, inhibidores de hsp90, composiciones que los contienen y utilización
AR104262A1 (es) Derivados de cromeno como inhibidores de las fosfoinositido-3 quinasas
AR100807A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR099495A1 (es) Derivados de amida, antagonistas de orexina
TR201901338T4 (tr) Kinaz İnhibitörleri Olarak Pirazolo-Piridin Türevleri
AR091208A1 (es) Derivados de piperidina
AR103397A1 (es) Oxoborazoles microbicidas
PE20211246A1 (es) Compuestos biciclicos para su uso como inhibidores de rip1 quinasa
AR113811A1 (es) Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos
AR091534A1 (es) Derivados de sulfonamida y metodos de uso de los mismos para mejorar la farmacocinetica de un farmaco